ONOlga V. Nikolaeva

Olga V. Nikolaeva

*This is an algorithmically generated author record based on publicly available information.

Olga V. Nikolaeva has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The experience of using succinate-containing crystalloid solution in the correction of COVID-19-associated endotheliopathy

    by Olga V. Nikolaeva, Ionas S. Simutis, Vyacheslav A. Ratnikov, Alexey N. Scheglov, Larisa B. Gaykovaya, Tatyana P. Zavyalova, Завьялова Татьяна Павловна

    BACKGROUND: Early experience with succinate-containing agents has demonstrated their effectiveness in controlling COVID-19-related systemic disease and coagulopathy. The work is aimed at studying the possibilities of infusion correction of COVID-19-associated endotheliopathy. AIM: To evaluate the effect of using meglumine sodium succinate 1.5% solution on the severity of COVID-19-associated endotheliopathy in patients with severe coronavirus infection. MATERIALS AND METHODS: Clinical and laboratory parameters of 53 patients in the intensive care unit with COVID-19 complicated by community-acquired bilateral polysegmental pneumonia were analyzed. The intensive care package for 27 patients (study group) included a daily infusion of a 1.5% solution of meglumine sodium succinate (Reamberin) in a daily dose of up to 10 ml/kg for a course of at least 11 days or during the entire stay in the department. The control group, which included 26 patients, received a similar volume of Ringer’s solution. At all stages of the study, the level of endotheliocytosis, homocysteine, fibrinogen, activated partial thromboplastin time, platelet count, and antithrombin III was determined. RESULTS: Assessment of the degree of endotheliopathy in the meglumine succinate group showed a significant decrease in the initially elevated levels of endothelemia and homocysteinemia at all stages of the study. The pattern of changes in the study group highly correlated (r values were in the range 0.90–0.96) with the dynamics of fibrinogenemia, platelet levels, and antithrombin III. CONCLUSIONS: The use of a succinate-containing infusion solution in patients with a new coronavirus infection promotes a more rapid and sustainable correction of COVID-19-associated endotheliopathy, which, in turn, is manifested by a decrease in the levels of endotheliocytosis, secondary markers of endotheliopathy, a platelet-protective effect and a decrease in heparin resistance.


  • Open Access

    Potential for infusion correction of COVID-19-associated endotheliopathy

    by Ionas S. Simutis, Viacheslav A. Ratnikov, Alexey N. Scheglov, Olga V. Nikolaeva, Gennady A. Boyarinov, Alexander A. Sapegin, Larisa B. Gaikovaya, Darya A. Evteeva, Ksenia N. Zamyatina, Бояринов Геннадий Андреевич, et al.

    Aim. To evaluate the relationship between the systemic inflammatory response and the severity of COVID-19-associated endotheliopathy and the effect of succinate-containing crystalloid solution (sodium meglumine succinate) on it in patients with severe COVID-19. Materials and methods. Clinical and laboratory parameters of 53 intensive care unit's patients with COVID-19 complicated by community-acquired bilateral multisegmental pneumonia were analyzed. Intensive therapy complex of 27 patients (study group) included daily infusion of 1.5% solution of sodium meglumine succinate (Reamberin) in the daily dose of 10 ml/kg for at least 11 days (or during the whole stay in the unit). A similar volume of Ringer's solution was present in the control group of 26 patients. The levels of endotheliocytosis, homocysteine, and systemic inflammatory response were determined at all stages of the study. Results. The evaluation of endotheliopathy degree in the meglumine succinate group showed a significant reduction of initially elevated levels of endotheliemia and homocysteinemia at all study stages. The pattern of changes in the study group was highly correlated (r=0.900.96) with the dynamics of systemic inflammatory response parameters-fibrinogenemia, C-reactive protein and interleukin-6 levels. As normalization of the immune imbalance, we regarded the termination of lymphopenia in the Reamberin group. Conclusion. Early inclusion of Reamberin infusion into intensive therapy of severe COVID-19, in comparison with Ringer's solution, leads to significant and stable correction of the severity of systemic inflammatory response, which in turn is naturally reflected in the severity of endothelial dysfunction, multiple organ failure, and also leads to a decrease in 28-day mortality.